The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma.

Vitellius, Carole; Fizanne, Lionel; Menager-Tabourel, Elodie; Nader, Joelle; Baize, Nathalie; Laly, Margot; Lermite, Emilie; Bertrais, Sandrine; Caroli-Bosc, F X

Vitellius, Carole; Fizanne, Lionel; Menager-Tabourel, Elodie; Nader, Joelle; Baize, Nathalie; Laly, Margot; Lermite, Emilie; Bertrais, Sandrine; Caroli-Bosc, F X.

Afiliación

Vitellius C; Department of Gastroenterology, University Hospital Centre, Angers, France.
Fizanne L; HIFIH, Laboratory, UNIV Angers, Université Bretagne Loire, Angers, France.
Menager-Tabourel E; Department of Gastroenterology, University Hospital Centre, Angers, France.
Nader J; HIFIH, Laboratory, UNIV Angers, Université Bretagne Loire, Angers, France.
Baize N; Department of Gastroenterology, University Hospital Centre, Angers, France.
Laly M; Department of Gastroenterology, University Hospital Centre, Angers, France.
Lermite E; Department of Digestive Surgery, University Hospital Centre, Angers, France.
Bertrais S; HIFIH, Laboratory, UNIV Angers, Université Bretagne Loire, Angers, France.
Caroli-Bosc FX; Department of Gastroenterology, University Hospital Centre, Angers, France.

Oncotarget ; 9(46): 28069-28082, 2018 Jun 15.

Article en En | MEDLINE | ID: mdl-29963262

Palabras clave

everolimus; gemcitabine; pancreatic cancer; zoledronic acid

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google